You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
SBC: Actinium Pharmaceuticals, Inc. Topic: 102ABSTRACT Despite treatment advances, the prognosis of adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and R/R diffuse large B-cell lymphoma (DLBCL) remains poor. Autologous T- cells modified to express a CD19-targeted chimeric antigen receptor (CAR T-cells) produce durable responses in subgroups of these patients, which has led to FDA approval of two su ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Controlled-release Microbeads to Replace Growth Factors in Fetal Bovine Serum
SBC: STEM CULTURES LLC Topic: 400Scientific Abstract: The frequent use of fetal bovine serum (FBS) to support cell cultures is challenged by lot-to-lot variability, supply constraints, pathogen contaminants and ethical questions. These issues have increased significance due to the burgeoning use of FBS in cell research and therapy development. FBS has been used for over a century to culture cells, but with the need to define cult ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
2-HOBA for Treatment of Pulmonary Hypertension
SBC: MTI Biotech Incorporated Topic: NHLBIPROJECT SUMMARY Although the ubiquity of metabolic problems in pulmonary hypertension (PH) has been known for more than a decade, a wealth of new details on the nature of this problem presents the opportunity for intervention. A combination of experimental work in cells and animals and early trials in humans, suggests that these metabolic problems are part of the causation for PH, and that inactiv ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Ultra-low Fouling and Anti-infective and Anti-thrombotic Nitric Oxide Releasing Intravascular Catheters
SBC: NYTRICX INC Topic: NHLBIAbstract Nytricx is developing a new class of Nitric Oxide (NO)-releasing intravascular medical catheters to combat infection and thrombosis associated with indwelling vascular catheters. NO gas is a natural anti-infective and anti-thrombotic human product principally released from blood vessels and immune cells. Nytricx NO-releasing technology to the catheter surfaces via a polymer matrix, mimics ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD
SBC: RIP ROAD, INC. Topic: NIAProject SummaryImpairment in instrumental activities of daily living (IADL) is a hallmark of Alzheimer’s disease (AD) dementia and a major source of patient and caregiver burden. Similarly to cognitive changes in AD, subtle difficulties in IADL may begin even before the stage of amnestic mild cognitive impairment (MCI). Recently, greater emphasis has been placed on preclinical AD, which consists ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin
SBC: POP Biotechnologies Inc. Topic: NCISummary Our goal is to commercialize interstitial chemo-phototherapy (I-CPT) as a new therapeutic option for locally advanced liver cancers. Doxorubicin (Dox) can be actively loaded into long circulating, serum-stable, porphyrin- phospholipid (PoP) liposomes and be released with 665-nm laser light (PhotoDox). This approach leads to vastly enhanced drug accumulation in irradiated tissues, resulting ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Teleconsent: Enabling informed consent for remote care and research
SBC: Doxy.me Inc. Topic: 100PROJECT SUMMARY . Informed consent is legal and ethical requirement in health care and research that assures that individuals have the autonomy to make informed care and research decisions at their own volition, under no coercion or undue influence, and with reasonable understanding of the risks, benefits, and responsibilities of their decisions as they would in-person. Obtaining informed consent ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
A Novel Remedy for Periodontal Bone Loss
SBC: PERIOMICS CARE LLC Topic: NIDCRPeriodontitis is a common chronic inflammatory disease characterized by destruction of the supporting structures of the teeth (the periodontal ligament and alveolar bone). The total prevalence of periodontitis in adults aged 30 years and older was 47.2% (representing about 64.7 million adults aged 30 years and older) and 70.1% in adults aged 65 years and older in the U.S. The current treatment opt ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Imaging Bacterial Infections in Vivo: First in Man Studies
SBC: Microbial Medical, Inc. Topic: NIAIDProject Summary/AbstractInfection is the major complication of virtually all medical devices. It is estimated that 2 million patients acquire a nosocomial infection in the US every year and the CDC estimates that the financial impact of these infections exceeds 5 billion dollars annually. At least half of these infections are directly associated with medical devices. Most commonly, the diagnosis o ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Disseminable Evidence-Based Treatment for the Dental Office: Virtual Exposure Tools for Dental Fear- neVR Fear the Dentist
SBC: VIRTUALLY BETTER INC Topic: NIDCRPROJECT SUMMARY/ABSTRACTEach year over 20 million adults with moderate fear and over 14 million adults with severe fear visit the dentist. Because fear portends poor future oral health, patients with dental fear come to experience their worst fears: pain, surgical procedures, and the need for more frequent dental visits. Avoidance is the natural and reinforced response, ironically guaranteeing a r ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health